Sort
48,018 grants matching “immunotherapy”
Cellular Processing Core
$495,712Ian McNiece · Johns Hopkins University · P01 · FY2008 · CA
Activation of Human Natural Killer Cell Function
$495,677Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Iron oxide nanotheranostics for breast cancer
$495,643Miqin Zhang · University Of Washington · R01 · FY2020 · EB
Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival
$495,627Richard Samuel Hotchkiss · Washington University · R35 · FY2020 · GM
Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival
$495,627Richard Samuel Hotchkiss · Washington University · R35 · FY2022 · GM
Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival
$495,627Richard Samuel Hotchkiss · Washington University · R35 · FY2021 · GM
Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival
$495,627Richard Samuel Hotchkiss · Washington University · R35 · FY2019 · GM
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
$495,600Emily H Cheng · Sloan-Kettering Inst Can Research · U54 · FY2023 · CA
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$495,583Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · CA
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
$495,564Stacey Deleria Finley · University Of Southern California · U01 · FY2024 · CA
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
$495,520Sana D Karam · University Of Colorado Denver · R01 · FY2024 · DE
Immune Regulation of Neuronal Injury and Repair
$495,471Kathryn Jane Jones · Indiana University Indianapolis · R01 · FY2013 · NS
Discovery of Drugs, Targets, and Target Strategies for Immunotherapy of CLL
$495,457Christoph Rader · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells
$495,420Bin Zhang · Northwestern University At Chicago · R01 · FY2020 · CA
Lineage heterogeneity and plasticity in lung cancer
$495,420Hideo Watanabe · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · CA
TARGETING HEPATOCYTE-DERIVED FACTORS TO IMPROVE THE EFFICACY OF IMMUNOTHERAPY IN PANCREATIC CANCER
$495,379Trustees Of The University Of Pennsylvania, The · · FY2021 · Department of the Army
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
$495,372Edgar G. Engleman · Stanford University · R01 · FY2025 · CA
A Therapeutic Vaccine for EBV-Associated Malignancies
$495,303Paul M. Lieberman · Wistar Institute · RC2 · FY2010 · CA
Project 2: Understanding the Cellular Origins of Melanoma
$495,239Anand K Ganesan · University Of California-Irvine · U54 · FY2021 · CA
Image-guided radiation-induced permeability (IGRIP) for IGDD
$495,216Stephen J. Kron · University Of Chicago · R01 · FY2016 · CA
Project 1: Evaluating stem-like T cells and improving efficacy of checkpoint inhibitors in NSCLC
$495,197Rafi Ahmed · Emory University · P50 · FY2020 · CA
Two Compartment Models to Improve Brain Tumor Therapy
$495,178Edward A Neuwelt · Oregon Health & Science University · R01 · FY2009 · CA
Molecular Determinants of Hemogenic Endothelium
$495,137Igor I Slukvin · University Of Wisconsin-Madison · R01 · FY2020 · HL
Molecular Determinants of Hemogenic Endothelium
$495,137Igor I Slukvin · University Of Wisconsin-Madison · R01 · FY2019 · HL
Molecular Determinants of Hemogenic Endothelium
$495,137Igor I Slukvin · University Of Wisconsin-Madison · R01 · FY2021 · HL